Explore 3 Stock Ideas & Industry Insights Download Free Report

Announcements

Palvella Therapeutics Files Q3 2026 Report

Palvella Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter ended September 30, 2026.

Vinay Lochav | 05 November 2026

Bryan T. Vaughn Sells 306 Labcorp Shares at $353.70

A Form 4 filed on November 5, 2026 reports that Bryan T. Vaughn, EVP and President, Diagnostics at Labcorp Holdings Inc., sold 306 shares of common stock on November 3, 2026 under a Rule 10b5-1 trading plan.

Manish Choudhary | 05 November 2026

SCYNEXIS Posts $22.4M Net Loss for Nine Months Ended Sept 2026

SCYNEXIS, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter ended September 30, 2026, and reporting a net loss of $22.360 million for the nine months ended on that date.

Shwetambri Chauhan | 05 November 2026

Sabre Q3 2026: Revenue Rises to $738M Amid Net Loss

Sabre Corporation filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the three and nine months ended September 30, 2026, disclosing continued revenue growth alongside a net loss from continuing operations and rising long-term debt.

Nitish Kishor | 05 November 2026

BlackRock TCP Capital Q3 2026: Net Assets Fall to $5.61 per Share

BlackRock TCP Capital Corp. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 5, 2026, reporting a net decrease in net assets from operations of $81,305,680 for the nine months ended September 30, 2026.

Aditi Sarkar | 05 November 2026

Portillo's Files Q3 2026 Report With 72.8M Shares Outstanding

Portillo's Inc. filed its quarterly report on Form 10-Q for the fiscal quarter ended September 27, 2026, with the SEC on November 5, 2026, reporting 72,766,838 shares of Class A common stock outstanding as of October 29, 2026.

Nitish Kishor | 05 November 2026

Shattuck Labs Files Q3 2026 Report With 101.8M Shares Out

Shattuck Labs, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 5, 2026, disclosing its financial position and operations as a clinical-stage biopharmaceutical company.

Aditi Sarkar | 05 November 2026

Portillo's Approves Restaurant Closures Outside Chicagoland

Portillo's Inc. filed a Form 8-K on November 5, 2026, disclosing third-quarter financial results and a Board-approved plan to close a mid-to-high single digit number of underperforming restaurants located outside of Chicagoland.

Shwetambri Chauhan | 05 November 2026

Veracyte Q3 2026: Total Assets Rise to $1.57 Billion

Veracyte, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter ended September 30, 2026, and reporting condensed consolidated financial results for the three and nine months ended on that date.

Aditi Sarkar | 05 November 2026

BlackRock TCP Capital Q3 2026 Results and Q4 Dividend Declared

BlackRock TCP Capital Corp. filed a Form 8-K on November 5, 2026, announcing its financial results for the third quarter ended September 30, 2026, and declaring a fourth-quarter dividend of $0.17 per share.

Aditi Sarkar | 05 November 2026
Support

Hi! How can we help you today?

Loading…